Comparison of Efficacy and Safety of Different Analgesic Modes in Minimally Invasive Esophagectomy for Esophageal Cancer

What this Trial Is About

Researchers are evaluating the pain relief effectiveness and safety of different pain management methods during and after minimally invasive esophagectomy surgery for esophageal cancer. This clinical trial compares various perioperative analgesic approaches to understand their impact on patient comfort and recovery. The study is conducted by the Cancer Institute and Hospital, Chinese Academy of Medical Sciences, and spans phases 2 and 3 of clinical research. Participants will be randomly assigned to one of three groups: postoperative NSAIDs alone, preemptive analgesia followed by postoperative NSAIDs, or use of a postoperative patient-controlled analgesia pump. The preemptive analgesia involves a single 50mg dose of flurbiprofen axetil given 30 minutes before anesthesia. The NSAIDs are given at 50mg twice daily after surgery. The analgesia pump delivers sufentanil and ondansetron in a controlled dose. These treatments are compared to assess their pain control effects during the perioperative period. During the study, pain scores will be recorded at multiple time points up to 72 hours after surgery, alongside assessments of bowel function, abdominal discomfort, opioid-related side effects, early mobility, hospital stay length, and infection rates. Participants will be monitored closely for safety and recovery outcomes. The total participation duration and follow-up extend through the immediate postoperative period and up to 60 days after surgery to capture relevant health events and recovery progress.

Perioperative Analgesia Modes in Minimally Invasive Esophagectomy